Natera stock
NTRANASDAQNatera, Inc., HealthcareISIN US6323071042
43Score 43 out of 100, Weak
Price and trend
64 / 100
Price history
+54% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 31).
The price is 26% below its 52-week high. Largest decline in 11 years: 78% (September 2021 to May 2022).
Chart figures for advanced users
- SMA 50$379.87
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$270.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)31
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$182.65
- The lowest closing price of the last twelve months.
- Resistance$436.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Natera, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $46.83B, is number 6 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.31B (up 35.9% year on year) and a loss of $208.16M.
- For fiscal 2026, analysts expect on average revenue of $3B (up 29.9%) and adjusted earnings per share of −$1.58.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 494 of 702 in Healthcare, median 53.
- Our model puts fair value at $95.47, with the price 238% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 42.6% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 70
- More cash than debtCash $1.1B, financial debt $238.84M.Stability 60
Weaknesses
- DilutionShare count up 69% since 2020.Capital allocation 18
- Above fair valuePrice 238% above the fair value of $95.47.Valuation 11
- Loss-makingLoss of $164.71M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and growth, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $68.19 and expensive above $159.12 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $79.20, at 8.1% it would be $119.47.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 37.4% on the twelve months before. Revenue has grown strongly since 2012, at around 48% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 65%, operating −13%, net −9%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported −$0.42 (expected −$0.28)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 68.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.58−9.9%
- Revenue
- $3B+2.9%
- Earnings per share
- −$0.47−68.6%
- Revenue
- $3.64B+3.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +17.3%The 2026 revenue range was completely reset after a strong quarter and implies about 31% revenue growth excluding true ups.
“The guide implies 31% revenue growth this year ex true ups, and we feel very good about hitting this range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $160.81M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sheena JonathanSale
6 Nov 2026, Board
- Shares
- 3,150
- Price
- $316.00
- Value
- $995,405
- Brophy Michael BurkesSale
3 Nov 2026, CHIEF FINANCIAL OFFICER
- Shares
- 470
- Price
- $391.49
- Value
- $184,000
- Sheena JonathanSale
2 Nov 2026, Board
- Shares
- 112
- Price
- $399.97
- Value
- $44,797
Show 74 more
- Rabinowitz MatthewSale
2 Nov 2026, EXECUTIVE CHAIRMAN
- Shares
- 748
- Price
- $400.02
- Value
- $299,214
- Rabinowitz DanielSale
2 Nov 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 341
- Price
- $400.05
- Value
- $136,416
- Moshkevich SolomonSale
2 Nov 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 3,419
- Price
- $409.77
- Value
- $1.4M
- Fesko JohnSale
2 Nov 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 302
- Price
- $400.01
- Value
- $120,804
- Chapman Steven LeonardSale
2 Nov 2026, CEO AND PRESIDENT
- Shares
- 3,801
- Price
- $411.80
- Value
- $1.57M
- Brophy Michael BurkesSale
2 Nov 2026, CHIEF FINANCIAL OFFICER
- Shares
- 325
- Price
- $399.99
- Value
- $129,998
- Brophy Michael BurkesSale
30 Oct 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,906
- Price
- $425.55
- Value
- $811,098
- Brophy Michael BurkesSale
28 Oct 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,178
- Price
- $426.46
- Value
- $502,372
- Sheena JonathanSale
28 Oct 2026, Board
- Shares
- 187
- Price
- $426.34
- Value
- $79,726
- Rabinowitz DanielSale
28 Oct 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 968
- Price
- $426.34
- Value
- $412,698
- Moshkevich SolomonSale
28 Oct 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 1,162
- Price
- $426.34
- Value
- $495,408
- Fesko JohnSale
28 Oct 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 898
- Price
- $426.34
- Value
- $382,854
- Chapman Steven LeonardSale
28 Oct 2026, CEO AND PRESIDENT
- Shares
- 3,430
- Price
- $426.34
- Value
- $1.46M
- Brophy Michael BurkesSale
28 Oct 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,198
- Price
- $426.34
- Value
- $510,756
- Sheena JonathanSale
27 Oct 2026, Board
- Shares
- 291
- Price
- $406.00
- Value
- $118,146
- Rabinowitz MatthewSale
27 Oct 2026, EXECUTIVE CHAIRMAN
- Shares
- 1,718
- Price
- $406.00
- Value
- $697,508
- Rabinowitz DanielSale
27 Oct 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 884
- Price
- $406.00
- Value
- $358,904
- Moshkevich SolomonSale
27 Oct 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 1,010
- Price
- $406.00
- Value
- $410,060
- Fesko JohnSale
27 Oct 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 781
- Price
- $406.00
- Value
- $317,086
- Chapman Steven LeonardSale
27 Oct 2026, CEO AND PRESIDENT
- Shares
- 2,264
- Price
- $406.00
- Value
- $919,184
- Brophy Michael BurkesSale
27 Oct 2026, CHIEF FINANCIAL OFFICER
- Shares
- 781
- Price
- $406.00
- Value
- $317,086
- Sheena JonathanSale
21 Oct 2026, Board
- Shares
- 3,150
- Price
- $410.55
- Value
- $1.29M
- Sheena JonathanSale
16 Oct 2026, Board
- Shares
- 1,500
- Price
- $402.47
- Value
- $603,710
- Rabinowitz MatthewSale
15 Oct 2026, EXECUTIVE CHAIRMAN
- Shares
- 50,000
- Price
- $402.64
- Value
- $20.13M
- Chapman Steven LeonardSale
1 Oct 2026, CEO AND PRESIDENT
- Shares
- 1,273
- Price
- $413.31
- Value
- $526,144
- Moshkevich SolomonSale
1 Oct 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 3,000
- Price
- $414.22
- Value
- $1.24M
- Sheena JonathanSale
23 Sept 2026, Board
- Shares
- 18,064
- Price
- $388.01
- Value
- $7.01M
- Sheena JonathanSale
16 Sept 2026, Board
- Shares
- 3,150
- Price
- $354.19
- Value
- $1.12M
- Sheena JonathanSale
15 Sept 2026, Board
- Shares
- 6,000
- Price
- $350.07
- Value
- $2.1M
- Rabinowitz MatthewSale
15 Sept 2026, EXECUTIVE CHAIRMAN
- Shares
- 52,000
- Price
- $347.29
- Value
- $18.06M
- Rabinowitz MatthewSale
14 Sept 2026, EXECUTIVE CHAIRMAN
- Shares
- 50,000
- Price
- $334.76
- Value
- $16.74M
- Rabinowitz MatthewSale
11 Sept 2026, EXECUTIVE CHAIRMAN
- Shares
- 50,000
- Price
- $327.97
- Value
- $16.4M
- Moshkevich SolomonSale
2 Sept 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 15,160
- Price
- $326.89
- Value
- $4.96M
- Moshkevich SolomonSale
1 Sept 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 3,000
- Price
- $320.73
- Value
- $962,194
- Chapman Steven LeonardSale
1 Sept 2026, CEO AND PRESIDENT
- Shares
- 1,698
- Price
- $320.99
- Value
- $545,041
- Fesko JohnSale
10 Aug 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 6,517
- Price
- $321.53
- Value
- $2.1M
- Sheena JonathanSale
10 Aug 2026, Board
- Shares
- 6,000
- Price
- $325.32
- Value
- $1.95M
- Rabinowitz MatthewSale
7 Aug 2026, EXECUTIVE CHAIRMAN
- Shares
- 2,000
- Price
- $320.90
- Value
- $641,800
- Sheena JonathanSale
7 Aug 2026, Board
- Shares
- 9,150
- Price
- $315.66
- Value
- $2.89M
- Brophy Michael BurkesSale
4 Aug 2026, CHIEF FINANCIAL OFFICER
- Shares
- 478
- Price
- $274.22
- Value
- $131,077
- Brophy Michael BurkesSale
3 Aug 2026, CHIEF FINANCIAL OFFICER
- Shares
- 317
- Price
- $267.99
- Value
- $84,953
- Chapman Steven LeonardSale
3 Aug 2026, CEO AND PRESIDENT
- Shares
- 3,076
- Price
- $266.39
- Value
- $819,431
- Fesko JohnSale
3 Aug 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 295
- Price
- $267.99
- Value
- $79,057
- Moshkevich SolomonSale
3 Aug 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 3,410
- Price
- $265.58
- Value
- $905,627
- Rabinowitz DanielSale
3 Aug 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 334
- Price
- $267.99
- Value
- $89,508
- Rabinowitz MatthewSale
3 Aug 2026, EXECUTIVE CHAIRMAN
- Shares
- 731
- Price
- $267.99
- Value
- $195,900
- Sheena JonathanSale
3 Aug 2026, Board
- Shares
- 109
- Price
- $267.99
- Value
- $29,211
- Brophy Michael BurkesSale
29 Jul 2026, CHIEF FINANCIAL OFFICER
- Shares
- 1,863
- Price
- $249.38
- Value
- $464,595
- Sheena JonathanSale
28 Jul 2026, Board
- Shares
- 191
- Price
- $254.07
- Value
- $48,527
- Rabinowitz DanielSale
28 Jul 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 1,003
- Price
- $254.07
- Value
- $254,833
- Moshkevich SolomonSale
28 Jul 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 1,204
- Price
- $254.07
- Value
- $305,901
- Fesko JohnSale
28 Jul 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 931
- Price
- $254.07
- Value
- $236,540
- Chapman Steven LeonardSale
28 Jul 2026, CEO AND PRESIDENT
- Shares
- 3,580
- Price
- $254.07
- Value
- $909,572
- Brophy Michael BurkesSale
28 Jul 2026, CHIEF FINANCIAL OFFICER
- Shares
- 2,419
- Price
- $253.96
- Value
- $614,336
- Sheena JonathanSale
27 Jul 2026, Board
- Shares
- 288
- Price
- $260.49
- Value
- $75,021
- Rabinowitz MatthewSale
27 Jul 2026, EXECUTIVE CHAIRMAN
- Shares
- 1,718
- Price
- $260.49
- Value
- $447,523
- Rabinowitz DanielSale
27 Jul 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 884
- Price
- $260.49
- Value
- $230,274
- Moshkevich SolomonSale
27 Jul 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 1,010
- Price
- $260.49
- Value
- $263,096
- Fesko JohnSale
27 Jul 2026, PRESIDENT, CHIEF BUS. OFFICER
- Shares
- 782
- Price
- $260.49
- Value
- $203,704
- Chapman Steven LeonardSale
27 Jul 2026, CEO AND PRESIDENT
- Shares
- 2,190
- Price
- $260.49
- Value
- $570,475
- Brophy Michael BurkesSale
27 Jul 2026, CHIEF FINANCIAL OFFICER
- Shares
- 782
- Price
- $260.49
- Value
- $203,704
- Sheena JonathanSale
15 Jul 2026, Board
- Shares
- 1,500
- Price
- $273.88
- Value
- $410,825
- Chapman Rowan ESale
15 Jul 2026, Board
- Shares
- 135
- Price
- $274.82
- Value
- $37,101
- Sheena JonathanSale
13 Jul 2026, Board
- Shares
- 3,150
- Price
- $265.68
- Value
- $836,898
- Rabinowitz MatthewSale
6 Jul 2026, EXECUTIVE CHAIRMAN
- Shares
- 1,000
- Price
- $280.00
- Value
- $280,000
- Rabinowitz DanielSale
1 Jul 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 16,800
- Price
- $272.29
- Value
- $4.57M
- Moshkevich SolomonSale
1 Jul 2026, PRESIDENT, CLINICALDIAGNOSTICS
- Shares
- 3,000
- Price
- $272.90
- Value
- $818,711
- Rabinowitz DanielSale
24 Jun 2026, SEC. AND CHIEF LEGAL OFFICER
- Shares
- 33,600
- Price
- $251.65
- Value
- $8.46M
- Rosenman HermSale
24 Jun 2026, Board
- Shares
- 16,530
- Price
- $250.00
- Value
- $4.13M
- Sheena JonathanSale
17 Jun 2026, Board
- Shares
- 1,500
- Price
- $219.87
- Value
- $329,810
- Chapman Rowan ESale
16 Jun 2026, Board
- Shares
- 2,964
- Price
- $216.78
- Value
- $642,536
- Sheena JonathanSale
15 Jun 2026, Board
- Shares
- 3,150
- Price
- $211.14
- Value
- $665,087
- Rabinowitz MatthewSale
15 Jun 2026, EXECUTIVE CHAIRMAN
- Shares
- 45,789
- Price
- $214.66
- Value
- $9.83M
- Rabinowitz MatthewSale
12 Jun 2026, EXECUTIVE CHAIRMAN
- Shares
- 50,000
- Price
- $214.03
- Value
- $10.7M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Natera
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- DanaherDHR $163.33B66
- WuXi AppTec603259.SS $68.42B85
- IDEXX LaboratoriesIDXX $54.99B79
- Agilent TechnologiesA $48.78B76
- WatersWAT $45.38B55
- IQVIA HoldingsIQV $44.68B67
- Mettler-Toledo InternationalMTD $34.43B76
- IlluminaILMN $31.68B70
ETFs that hold Natera
Held by 75 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 5.13% | 0.50% | €127.06M |
| Harbor Health Care UCITS ETF AccW311 | 4.02% | 0.89% | €11.61M |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 2.29% | 0.25% | €44.3M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 1.91% | 0.40% | €1.49B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.81% | 0.49% | €318.39M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.77% | 0.12% | €1.34B |
| HAN-GINS Tech Megatrend Equal Weight UCITS ETF AccT3KE | 0.76% | 0.59% | €96.5M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.73% | 0.30% | €51.58M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Overvalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.